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Abstract - This study aimed to determine the prevalence and mutational patterns of lamivudine-resistant hepatitis B virus 
(HBV) strains in chronically infected Serbian patients. The study included 154 patients on long-term lamivudine mono-
therapy. Resistance-associated mutations were identified by direct sequencing of the S/P gene. The genotypic resistance 
to lamivudine was confirmed in 54.5% of patients. Three primary resistance-associated mutations were found: rtM204V 
(55.9%), rtM204I (40.5%), rtA181T (3.6%) and two compensatory mutations rtV173L (17.8%) and rtL180M (67.8%). 
Seven mutational patterns were discovered with rtL180M+rtM204V being dominant (41.6%). The presence of resistance-
associated mutations was correlated to the older age of patients, the presence of clinically relevant HBsAg mutations and 
higher values of viral load. No correlation with HBV genotypes, subgenotypes or HBsAg subtypes was observed. High 
prevalence of resistance supports the use of genotypic testing in monitoring patients on lamivudine therapy and selecting 
those who would benefit from therapy with newly developed nucleos(t)ide analogs. 
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INTRODUCTION
Hepatitis B virus (HBV) infection is a major cause of 
acute and chronic hepatitis and of its long-term com-
plications. About 350 million people are currently 
infected with HBV worldwide and approximately 1 
million die of liver failure, cirrhosis and hepatocel-
lular carcinoma (HCC) each year (Lavanchy, 2005, 
Weber et al., 2011).
It has been shown that the risk of liver disease 
progression in patients with chronic hepatitis is as-
sociated with elevated HBV DNA levels (Chen et al., 
2006, Iloeje et al., 2006). Therefore, the goal of ther-
apy for chronic hepatitis patients is to delay or pre-
vent the progression of liver disease by suppressing 
long-term HBV DNA replication (Negro, 2011). The 
development and introduction of nucleos(t)ide ana-
logs (NA) has played a major part in the progress of 
chronic hepatitis B treatment that has occurred over 
the past decade. Since the introduction of lamivu-
dine (LMV) in 1998, new drugs have been developed 
and today a large number of patients is on long-term 
NA therapy. Currently, lamivudine, adefovir, ente-
cavir, telbivudine and tenofovir have been approved 
worldwide for the treatment of chronic B hepatitis 
(Chien and Liaw, 2008). 
In Serbia, tenofovir, the representative of the latest 
generation of NA, is currently available for the treat-
ment of HBV infection, but until recently, all patients 
requiring treatment were on long-term lamivudine 602 IVANA LAZAREVIĆ ET AL.
monotherapy. Lamivudine is a deoxycytidine analog 
that inhibits HBV DNA synthesis through chain ter-
mination. It has been shown to be effective in reduc-
ing HBV DNA levels, normalizing serum transami-
nases and improving histological indices in patients 
with both HBeAg positive and negative disease (Lok 
and McMahon, 2004). The major drawback of lami-
vudine treatment is the high rate of viral resistance 
related to mutations. Mutations conferring resistance 
to NA are located in the reverse transcriptase (RT) 
domain of the HBV polymerase gene. The kinetics of 
replacement of the wild-type virus in liver cells by a 
dominant mutant is slow because resistant mutants 
mainly infect new uninfected cells. LMV resistance 
increases progressively over the course of treatment; 
14-36% after 1 year of treatment, increasing to 38%, 
49% and 66% after 2, 3, and 4 years of treatment, re-
spectively (Lau et al., 2000, Liaw et al., 2000, Lai et 
al. 2003).
Most lamivudine resistant HBV strains are char-
acterized by an exchange of the methionine by an 
isoleucine or a valine (rtM204I/V mutants) in the 
YMDD motif, the active site within RT (aa203-206). 
LMV resistance by the HBV mutations at position 
204 is due to changes in the van der Waals forces (or 
the intramolecular interactions) that results in the 
repositioning of the antiviral agent as well as steric 
hindrance between the sulfur atom in LMV and the 
rtM204I/V side chain (Bartholomeusz and Locarni-
ni 2006). 
The change at position 204 is usually not detected 
as a single mutation but in combination with differ-
ent secondary or compensatory mutations. The role 
of compensatory mutations is to restore functional 
defects in viral polymerase activity (i.e., replication 
fitness) associated with primary drug resistance (Lok 
et al., 2007a). Five major compensatory mutations 
have so far been reported (rtL80I, rtI169T, rtV173L, 
rtL180M, rtT184S) and they are associated with pri-
mary mutations in nine major patterns (Bartholom-
eusz and Locarnini, 2006). As an exception, one of 
the patterns includes the existence of a single prima-
ry mutation (rtA181T) outside of the YMDD motif 
that was first detected in a patient with increasing 
HBV DNA levels during LMV treatment without the 
classical LMV resistance (Yeh et al., 2000). 
The aims of the present study were: (1) to de-
termine the prevalence and mutational patterns of 
lamivudine-resistant strains in Serbian patients on 
long-term therapy, and (2) to correlate the presence 
of genotypic resistance to lamivudine with demo-
graphic and other virological parameters.
MATERIALS AND METHODS
Patients
The study comprised 154 plasma samples, collected 
over a 6-year period (2006-2012) from patients with 
chronic hepatitis B treated at the Clinics of Infectious 
and Tropical Diseases in Belgrade. The diagnosis was 
based on HBsAg positivity for >6 months and his-
topathological verification by liver biopsy. One hun-
dred and eighteen patients were male (76.6 %) and 36 
were female (23.4%). Age ranged from 9 to 76 years 
(mean: 44.4±15.5 years). All patients were on lami-
vudine monotherapy for at least two years. Informed 
consent for participating in this study was obtained 
from all patients and the study was approved by the 
Ethics Committee of Faculty of Medicine, University 
of Belgrade No. 29/VI-12.
Isolation and amplification of viral DNA
Isolation of viral DNA was carried out using a 
QIAmp Blood Mini Kit (QIAGEN GmBH, Hilden, 
Germany) according to the manufacturer’s instruc-
tions. HBV DNA was amplified using nested PCR 
that targeted a 487-bp region of the S/P gene. Ampli-
fication was performed using the following primers: 
252  (5’-AGACTCGTGGTGGACTTCTCT-3’)/1309 
(5’-AGAATGTTTGCTCCAGACC-3’)  as  exter-
nal  primers  and  377  (5’-GGATGTGTCTGCG-
GCGTTT-3’)/840 (5’-ACCCCATCTTTTTGTTTT-
GTTAGG-3’) as internal primers, as described pre-
viously (Zollner et al., 2002). After both reactions, 
a  487-bp  fragment  was  obtained  and  detected  by 
ethidium bromide staining in an agarose gel. LMV-RESISTANT HBV STRAINS IN SERBIA 603
DNA purification and sequencing
Nested-PCR products were purified using the QIA-
GEN MinElute Purification Kit (QIAGEN GmBH, 
Hilden, Germany), according to manufacturer’s in-
structions. For cycle sequencing reactions, internal 
PCR primers and a Big Dye Terminator v3.1 Cycle 
Sequencing  Kit  (Applied  Biosystems,  Foster  City, 
CA, USA) were used. Sequencing was carried out 
in an automatic sequencer (ABI PRISM 310 Genetic 
Analyzer; Applied Biosystems). Sense and antisense 
strands  were  sequenced  and  compared.  A  444-nt 
fragment of the S gene (nt 394-837), which com-
prised codons 80-227 of the HBsAg molecule, was 
selected for analysis.
Identification of lamivudine-resistance mutations and 
HBsAg mutations
For  identification  of  lamivudine-resistance  muta-
tions and HBsAg mutations, all obtained sequences 
were compared with a reference wild-type sequence 
of  the  same  genotype  in  BioEdit  software  (Hall, 
1999).  Amino  acid  substitutions  were  discovered 
by applying open reading frames for either P or S 
gene.
Identification of HBV genotypes, subgenotypes,  
HBsAg subtypes
The viral genotype and subgenotype was identified 
by phylogenetic analysis. The nucleotide sequences 
were aligned pairwise using ClustalW, and a phylo-
genetic tree was constructed by the neighbor-joining 
method  and  Kimura  two-parameter  algorithm  in 
MEGA software (version 5.05) (Tamura et al., 2011). 
Statistical significance of phylogeny was estimated by 
bootstrap analysis with 1 000 pseudoreplicate data-
sets.
The HBsAg subtype was deduced from the se-
quence of the same S gene region used for genotyp-
ing, based on identifying amino acids at positions 
122 (Lys/Arg for d/y determinants), 160 (Lys/Arg for 
w/r determinants), 127 (Pro/Thr/Leu-Ile for w2/w3/
w4), and in the case of Arg122 Pro127 Lys160, also at 
positions 159 (Ala/not Ala for ayw1/ayw2 and ayw4) 
and 140 (not Ser/Ser for ayw2/ayw4).
HBV DNA Quantitation
For determination of HBV DNA level in plasma, an 
in-house real-time PCR protocol was performed, us-
ing pre-designed primers and probes from Applied 
Biosystems,  TaqMan  Universal  PCR  Master  Mix 
(Applied Biosystems) and 4 whole genome stand-
ards 103-106 copies/μL (Clonit S.r.I., Milano, Italy). 
All HBV DNA values are reported in IU/ml; values 
given as copies/ml were converted to IU/ml by divi-
sion by 5.6. For the presentation of HBV DNA levels 
logarithmic scale was used.
Statistical analysis
Data  statistical  analysis  was  performed  using  the 
SPSS software package 20.0 (IBM SPSS Statistics for 
Windows,  Armonk,  NY,  USA).  Chi-squared  test, 
Student t-test, Mann-Whitney U-test and Spearman’s 
rank correlation test were used for comparisons and 
correlations of groups.
RESULTS
Plasma samples of 154 patients on long-term lami-
vudine therapy were tested for the presence of HBV 
DNA. The majority of patients were positive for HBV 
DNA – 132 (85.7%), while 22 (14.3%) did not have 
detectable HBV in peripheral blood. Positive sam-
ples were tested by real-time PCR for determination 
of viral load. Viral load values varied from 3.65 to 10 
log IU/mL with the mean value of 6.04±1.86 log IU/
mL.
For determination of viral genotypes and subg-
enotypes, a phylogenetic tree (not shown) was con-
structed based on sequences of the 444-nt fragment of 
the S/P gene (nt 394-837). Two HBV genotypes were 
encountered: D in 114 (86.4%) and A in 18 (13.6%) 
patients. All genotype A isolates clustered with the 
representative sequence for European A2 subgeno-
type in the phylogenetic tree, whereas genotype D 
isolates belonged to three different subgenotypes: 8 604 IVANA LAZAREVIĆ ET AL.
to D1 (6.1%), 33 to D2 (25%), and 73 to D3 (55.3%). 
HBsAg subtypes were deduced from the sequence by 
identifying amino acids at positions 122, 160, 127, 
159 and 140. All of the genotype A isolates displayed 
a sequence characteristic for adw2 HBsAg subtype. 
Among genotype D isolates, four HBsAg subtypes 
were identified: ayw1, ayw2, ayw3 and ayw4, where 
ayw2 was predominant (56.8%). 
The genotypic resistance to lamivudine was con-
firmed in 84 (54.5%) of 154 patients. Among inves-
tigated isolates, three primary resistance-associated 
mutations were found, 2 within the YMDD motif 
(aa203-206)  of  the  RT  region  (rtM204V  and  rt-
M204I) and one outside the YMDD motif – rtA181T. 
Most isolates (96.4%) displayed primary resistance-
associated mutations in the YMDD motif, while in 
three (3.6%) isolates resistance was the consequence 
of  non-YMDD  mutation.  The  dominant  primary 
resistance-associated mutation was rtM204V. Com-
pensatory mutations were frequent since at least one 
was found in 69% of isolates, and they were located 
Fig.1. Frequencies (%) of discovered resistance-associated mutations.
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on two positions, rtV173L and rtL180M. The fre-
quencies of discovered resistance-associated muta-
tions are shown in Fig. 1.
Combinations  of  primary  and  compensatory 
mutations,  i.e.  mutational  patterns,  were  also  in-
vestigated.  Seven  patterns  were  discovered  in  this 
study group. Three patterns comprised 3 mutations; 
another 3 patterns comprised a combination of one 
primary and one compensatory mutation, while 2 
patterns consisted of a single primary mutation. The 
predominant pattern was rtL180M+rtM204V found 
in 41.6% of all resistant isolates, followed by a pattern 
comprising single rtM204I found in 27.4%. The fre-
quencies of lamivudine-resistant mutational patterns 
among the investigated isolates are shown in Fig.2.
HBsAg  mutations  associated  with  diagnostic 
problems and evasion of HBIg therapy and vaccine-
induced  immunity  were  discovered  in  45(34.1%) 
of 154 tested isolates. The discovered HBsAg muta-
tions included single base substitutions at 17 ami-
no acid residues: 100, 101, 110, 120, 126, 128, 129, 
130, 131,133, 134, 140, 143, 144, 145, 164 and 166, 
whereas in one isolate a 6-nt insertion was found that 
added three codons to HBsAg: 115-117. 
The  genotypic  resistance  was  not  statistically 
associated  with  any  of  the  discovered  genotypes, 
subgenotypes or HBsAg subtypes. Genotype D was 
significantly associated with a resistant pattern that 
included the presence of a single mutation rtM204I 
without compensatory mutations (ρ=0.183, P=0.03), 
since this pattern was exclusively found in genotype 
D. In addition, most isolates that displayed clinically 
relevant HBsAg mutations belonged to D genotype, 
thus making the correlation with this genotype high-
ly significant (ρ=0.239, P=0.006). 
The  presence  of  resistance-associated  muta-
tions was further correlated to older age of patients 
(ρ=0.289,  P=0.001)  and  presence  of  clinically  rel-
evant  HBsAg  mutations  (ρ=0.239,  P=0.006).  The 
correlation of resistance-associated mutations with 
higher values of viral load was at statistical border-
line (ρ=0.242, P=0.06).
DISCUSSION
Nucleos(t)ide analogs revolutionized the treatment 
of chronic HBV infection because of sustained sup-
pression of viral replication and remission of liver 
disease. However, long-term NA therapy exposes 
patients to the risk of a selection of drug-resistant 
mutants  (Papatheodoridis  et  al.,  2005,  Locarnini 
and Mason, 2006). Because of the spontaneous var-
iability of the HBV genome, NA pressure could se-
lect for viral quasispecies that exhibit the best repli-
cation capacity in the presence of an antiviral agent. 
Genotypic antiviral resistance designates the pres-
ence of a unique nucleotide and the corresponding 
deduced amino acid mutations in the drug target 
gene  that  have  been  previously  demonstrated  to 
be associated with antiviral resistance (Lok et al., 
2007a). 
Lamivudine  monotherapy  is  responsible  for 
fastest  drug-resistance  selection  among  NA.  Ac-
cording to Lai et al. (2003), 14%-32% of patients 
become resistant to the drug each year after treat-
ment was initiated, and more than 80% are resistant 
after 48 months of treatment. Two previous studies 
concluded that the rate of LMV resistance was ap-
proximately 20% per annum and that after 5 years 
it reached 69% (Benhamou et al., 1999, Liaw et al., 
2000). This is in accordance with the present study, 
which demonstrated a high rate (54.5%) of con-
firmed genotypic resistance in patients treated for 
at least two years. Because of the high probability 
of HBV resistance, LAM monotherapy is not cur-
rently  considered  an  optimal  first-line  long-term 
treatment for chronic hepatitis B (Lok and McMa-
hon, 2007b). However, it is still widely used, mostly 
because of its low cost.
The  HBV  genotype,  subgenotype  and  HBsAg 
subtype distribution among investigated isolates was 
in accordance with previously published data for Ser-
bian patients (Lazarević et al. 2010). Accordance was 
also observed for the frequency of clinically relevant 
HBsAg mutations that were present in approximately 
1/3 of patients on long-term NA therapy in the previ-
ous and present study.606 IVANA LAZAREVIĆ ET AL.
The association of specific HBV genotype and 
HBsAg  subtype  with  the  development  of  antivi-
ral drug resistance was first suggested by Zollner et 
al. (2001). This study reported that an adw HBsAg 
subtype had a 20-fold higher risk of lamivudine re-
sistance than ayw. Later, Verschuere et al. (2005) re-
ported that the rate of resistance after 1 year of lami-
vudine therapy is higher in patients with genotype 
A infection than in patients with genotype D infec-
tion, but YMDD variants appear earlier in genotype 
D. However, in the present study the occurrence of 
resistance was similar in genotypes D (65.8%) and 
A  (50%)  and  no  statistical  difference  was  found. 
A few other studies (Buti et al., 2002, Akuta et al., 
2003, Moskovitz et al., 2005) also reported that the 
emergence of lamivudine resistance was comparable 
between genotypes A and D. Finally, a more recent 
meta-analysis consistently found no significant as-
sociation between HBV genotype and response to 
nucleos(t)ide analogs (Wiegand et al., 2008). 
The differences between genotypes A and D with 
respect to mutational pattern during the develop-
ment of lamivudine resistance were also suggested 
(Zollner et al., 2004). In this study, all seven muta-
tional patterns were present in genotype D isolates, 
while genotype A isolates displayed only three, where 
rtL180M+rtM204V  was  dominant  and  also  more 
frequent than in genotype D (38.9% in A vs. 24.6% 
in D). This is consistent with the report by Zollner et 
al. (2004) that genotype A had a 6-fold higher prob-
ability of selecting a valine substitution compared to 
genotype D. Also consistent with previous reports, 
the findings of this study conclude that mutation rt-
M204I was more frequent in genotype D and that the 
pattern including single rtM204I, without compen-
satory mutations, was found exclusively in genotype 
D isolates.
Compensatory  mutation  rtL180M  alone  was 
found  to  confer  modest  resistance  to  lamivudine. 
However, mutations in the B domain of RT (rtL180V 
and or rtV173L) were found to restore the replication 
capacity nearly to that of the wild-type virus (Dela-
ney et al. 2003). This could explain the frequently 
observed  combined  mutation  patterns  of  primary 
and compensatory mutations in chronically infected 
patients. Not surprisingly and consistent with other 
reports (Tacke et al., 2004, Thompson et al., 2007), 
the  two  most  prevalent  mutation  patterns  in  this 
study were L180M+rtM204V followed by unassoci-
ated rtM204I.
Despite  being  outside  the  YMDD  motif,  the 
rtA181T mutation may alter the position of codon 
rtM204, resulting in an allosteric change of the cata-
lytic site, and it may also alter the positioning of LMV 
relative  to  rtM204  (Bartholomeusz  and  Locarnini 
2006). This may potentially lead to a mechanism for 
discrimination between the natural substrate and the 
nucleoside analog, resulting in resistance. Since it is 
often occurs in the absence of rtM204V/I, it is consid-
ered a primary resistance mutation (Yeh et al., 2000). 
This mutation at codon rtA181T was not so frequent 
in the investigated group but since it is also selected 
during adefovir treatment, it could be responsible for 
cross-resistance between these two NAs. 
Lamivudine-associated  resistance  mutations  in 
the P gene are responsible for corresponding changes 
in the S gene and HBsAg, and therefore can affect 
antigenicity. Thus, all isolates that display resistance 
mutations are potential vaccine-escape mutants (Tor-
resi et al., 2002). Besides, HBsAg mutations that were 
independent  of  resistance-associated  polymerase 
mutations were more often found in treated patients 
and it is believed that some of them are triggered by 
LAM. The prevalence of clinically relevant HBsAg 
mutations was high in the present study (34.1%) and 
their presence was significantly correlated with gen-
otype D, which can be explained by the established 
higher variability of this genotype (De Maddalena et 
al., 2007).
In conclusion, the genotypic resistance to lami-
vudine monotherapy was found in more than half 
of investigated patients on long-term treatment. It 
was shown that the older age of patients and higher 
viral load were predictive factors for the occurrence 
of resistance. High prevalence of resistance supports 
the use of genotypic testing in monitoring patients 
on  lamivudine  therapy  and  selecting  those  who  LMV-RESISTANT HBV STRAINS IN SERBIA 607
would benefit from therapy with newly developed 
nucleos(t)ide analogs. 
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